What changed: Metastatic pancreatic ductal adenocarcinoma
Every dated change on the records linked to Metastatic pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 3
- 2026ApprovalDaraxonrasibDaraxonrasib approved in US
Metastatic pancreatic cancer (previously treated)
- 2026Trial resultRASolute 302RASolute 302 reported
OS 13.
- 2026MilestoneRASolute 302RASolute 302: daraxonrasib lengthens survival after first-line chemotherapy, the first RAS inhibitor to do so
A milestone in how this cancer is treated.
June 2024 · 1
2024 · 4
- 2024ApprovalIrinotecan (and liposomal irinotecan)Irinotecan (and liposomal irinotecan) approved in US
Liposomal irinotecan in NALIRIFOX first-line metastatic pancreatic cancer
- 2024Trial resultAVENGER 500AVENGER 500 reported
No overall survival benefit from adding devimistat to modified FOLFIRINOX.
- 2024Trial resultLAPISLAPIS reported
Primary overall survival endpoint not met.
- 2024MilestoneZenocutuzumabZenocutuzumab approved for NRG1 fusion-positive pancreatic cancer
A milestone in how this cancer is treated.
2023 · 3
- 2023Trial resultNAPOLI 3NAPOLI 3 reported
OS HR 0.
- 2023Trial resultNOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer) reported
Overall survival improved with nimotuzumab plus gemcitabine in KRAS wild-type disease.
- 2023MilestoneNAPOLI 3NAPOLI 3: NALIRIFOX beats gemcitabine plus nab-paclitaxel first line
A milestone in how this cancer is treated.
2021 · 1
December 2019 · 1
2019 · 2
2016 · 1
2015 · 1
2013 · 1
2011 · 2
- 2011ApprovalFOLFIRINOX / mFOLFIRINOXFOLFIRINOX / mFOLFIRINOX approved in Global
Metastatic PDAC (PRODIGE 4 / ACCORD 11; component drugs generic)
- 2011MilestoneFOLFIRINOX / mFOLFIRINOXPRODIGE 4/ACCORD 11: FOLFIRINOX lengthens survival over gemcitabine in fit patients
A milestone in how this cancer is treated.